ArticleNature communications2025
Urinary Complement proteome strongly linked to diabetic kidney disease progression.
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Natural product therapy in diabetic kidney disease: emerging multiomics-mediated signalling pathway and molecular target.Chinese medicine · 2026Review
- Advances in Complement Research: from Pathophysiology to Precision Medicine.Physiology (Bethesda, Md.) · 2026Review
- Glomerular Capillary C4d Staining in Native Kidney Biopsies: Associations with Proteinuric Phenotype and Reduced Likelihood of Early Proteinuria Remission.Diagnostics (Basel, Switzerland) · 2026Article
- Pathology-Anchored Biomarker Research Progress for the Early Diagnosis of Diabetic Kidney Disease: From Pathological Association to Early Validation.Biomedicines · 2026Review
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- Effect of complement 3/5 knockout on renal proteomics landscape after ischemia and reperfusion injury in rats.Physiological reports · 2026Article
- Molecular mechanisms and novel therapeutic targets of diabetic kidney disease.Chinese medical journal · 2026Review
- Emerging Urinary Biomarkers and Innovative Technologies for the Early Detection and Personalized Management of Chronic Kidney Disease.International journal of molecular sciences · 2026Review
- Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies.International journal of molecular sciences · 2026Review
- Spatial metabolomics: A new tool for unravelling the metabolic disorders and heterogeneity in diabetic kidney disease (Review).International journal of molecular medicine · 2026Review
- The Role of Complement Component C5a in the Pathogenesis of Diabetic Kidney Disease: A New Kid on the Block?Cureus · 2026Review
- From albuminuria to multi-omics signatures: emerging biomarkers and drug targets for early-stage chronic kidney disease.Frontiers in pharmacology · 2026Review
- Progress in the study of the role of C5a-induced tubular cell senescence in the progression of diabetic kidney disease.Annals of medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Zaipul I Md Dom *Research Division, Joslin Diabetes Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3503-7391
Salina Moon *Research Division, Joslin Diabetes Center, Boston, MA, USA.
Eiichiro SatakeResearch Division, Joslin Diabetes Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9784-4423
Daigoro HirohamaRenal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1885-1263
Nicholette D PalmerDepartment of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID http://orcid.org/0000-0001-8883-2511
Heather LampertResearch Division, Joslin Diabetes Center, Boston, MA, USA.
Linda H FicocielloResearch Division, Joslin Diabetes Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3523-0028
Amin AbediniRenal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8875-0070
Karen FernandezResearch Division, Joslin Diabetes Center, Boston, MA, USA.
Xiujie LiangRenal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-3471-1068
Sara PickettResearch Division, Joslin Diabetes Center, Boston, MA, USA.
Jonathan LevinsohnRenal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Kristina O'NeilResearch Division, Joslin Diabetes Center, Boston, MA, USA.
Simon T DillonDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Michael MauerDepartment of Pediatrics, School of Medicine, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0001-7301-9616
Andrzej T GaleckiDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Barry I FreedmanDepartment of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID http://orcid.org/0000-0003-0275-5530
Katalin SusztakRenal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1005-3726
Alessandro DoriaResearch Division, Joslin Diabetes Center, Boston, MA, USA.
Andrzej S KrolewskiResearch Division, Joslin Diabetes Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1705-2953
Monika A NiewczasResearch Division, Joslin Diabetes Center, Boston, MA, USA. monika.niewczas@joslin.harvard.edu.ORCID http://orcid.org/0000-0003-2371-595X
Funding
SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 1986 to 2026
$50.5MPERL: A multicenter clinical trial of allopurinol to prevent GFR loss in T1DUC4DK101108 · NIDDK · JOSLIN DIABETES CENTER · PI DORIA, ALESSANDRO, MAUER, S. MICHAEL · 2013 to 2018
$31.6MTransgenic CoreP30DK057521 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FLOREZ, JOSE CARLOS · 2000 to 2019
$31.4MResearch Education CoreP30AG024824 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Neil Alexander · 2004 to 2026
$29.2MTumor necrosis factor superfamily of ligands and receptors in progressive renal decline in diabetesR01DK041526 · NIDDK · JOSLIN DIABETES CENTER · PI KROLEWSKI, ANDRZEJ S · 1990 to 2018
$7.8MEpigenetics of Chronic Kidney DiseaseR01DK087635 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KATALIN SUSZTAK · 2009 to 2026
$7.0MAPOL1 associated kidney diseaseR01DK105821 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SUSZTAK, KATALIN · 2016 to 2024
$4.6MSubclinical CVD in African American Type 2 DiabeticsR01DK071891 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FREEDMAN, BARRY IRA · 2007 to 2016
$4.5MEpidemiology of cardiovascular disease in diabetesR01HL067348 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BOWDEN, DONALD W · 2001 to 2004
$4.3MCerebrovascular Disease and Cognitive Performance in African AmericansR01NS075107 · NINDS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DIVERS, JASMIN, FREEDMAN, BARRY IRA · 2011 to 2015
$2.8MDevelopment of Prognostic Algorithms to Identify Subjects at High Risk of ESKD in Type 2 DiabetesR01DK126799 · NIDDK · JOSLIN DIABETES CENTER · PI KROLEWSKI, ANDRZEJ S · 2021 to 2024
$2.7MTraining CoreTL1DK143326 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Wei Tong · 2024 to 2026
$2.5MHearst Foundations (Hearst Foundation, Inc.) William Randolph Hearst Foundation FellowshipJDRF 17-2012-377JDRF 5-CDA-2015-89-A-BNHLBI NIH HHS R01 HL067348NIA NIH HHS P30 AG024824NIDDK NIH HHS P30 DK036836NIDDK NIH HHS P30 DK057521NIDDK NIH HHS R01 DK041526NIDDK NIH HHS R01 DK071891NIDDK NIH HHS R01 DK076007NIDDK NIH HHS R01 DK087635NIDDK NIH HHS R01 DK105821NIDDK NIH HHS R01 DK123459NIDDK NIH HHS R01 DK126799NIDDK NIH HHS R03 DK094484NIDDK NIH HHS R34 DK097808NIDDK NIH HHS R61 DK131915NIDDK NIH HHS TL1 DK143326NIDDK NIH HHS UC4 DK101108NINDS NIH HHS R01 NS075107U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL67348 (PI Dr. Bowden)U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) P30DK036836 (to Joslin Diabetes Center)U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) P30DK057521U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK041526U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK071891U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK076007U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK087635U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK105821U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK123459U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK126799U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01NS075107U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R03DK094484U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R34DK097808U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R61DK131915U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) UC4DK101108U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) P30AG024824
Abstract
Diabetic kidney disease (DKD) progression is not well understood. Using high-throughput proteomics, biostatistical, pathway and machine learning tools, we examine the urinary Complement proteome in two prospective cohorts with type 1 or 2 diabetes and advanced DKD followed for 1,804 person-years. The top 5% urinary proteins representing multiple components of the Complement system (C2, C5a, CL-K1, C6, CFH and C7) are robustly associated with 10-year kidney failure risk, independent of clinical covariates. We confirm the top proteins in three early-to-moderate DKD cohorts (2,982 person-years). Associations are especially pronounced in advanced kidney disease stages, similar between the two diabetes types and far stronger for urinary than circulating proteins. We also observe increased Complement protein and single cell/spatial RNA expressions in diabetic kidney tissue. Here, our study shows Complement engagement in DKD progression and lays the groundwork for developing biomarker-guided treatments.
Indexed as
Complement System ProteinsDiabetic NephropathiesProteomeAdultAgedBiomarkersDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Disease ProgressionFemaleHumansKidneyMaleMiddle AgedProspective StudiesProteomicsBiomarkersComplement System ProteinsProteome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.